

TREATMENT OF POOR CANCER PATIENTS
SELECTED DRUGS LIST
SECOND TENDER 2019-2020

1	SAMI PHARMACEUTICALS	INJ GCSF (NEOFIL) 300 mcg
2	ALPHA EVOLUTION	TAB OLAPARIB (OLANIB) 150 mg
3	HIMMEL PHARMA	INJ CARBOPLATIN (CARPLATU) 450 mg
4	PHARMASOL LIMITED	INJ METHOTREXATE (Trexate) 1000 mg
5	PHARMASOL LIMITED	CAP THALIDOMIDE (THALIMID) 100 mg
6	MARTIN DOW	INJ CETUXIMAB (ERBITUX) 100 mg
7	PHARMEDIC	INJ 5 FU (PHARMAURACIL) 500 mg
8	PHARMEDIC	INJ 5 FU (PHARMAURACIL) 250 mg
9	PHARMEDIC	INJ LEUCOVORIN (LEUCOCIN) 50 mg
10	PHARMEDIC	INJ MESNA(MESNAL) 400 mg
11	PHARMEDIC	INJ BLEOMYCIN (BLEOMYCIN) 15 mg
12	PHARMEDIC	INJ CYTARABINE(CYTOCIN) 100 mg
13	PHARMEDIC	INJ CYTARABINE(CYTOCIN) 500 mg
14	PHARMEDIC	INJ ETOPOSIDE (TOPOSIDE) 100 mg
15	PHARMEDIC	INJ CARBOPLATIN (PHARMAPLATIN) 150 mg
16	PHARMEDIC	INJ CISPLATIN (CEPLATIN) 50 mg
17	PHARMEDIC	INJ VINBLASTINE(VINBLAS) 10 mg
18	PHARMEDIC	INJ VINCRISTINE (PHARMACRISTINE) 1 mg
19	PHARMEDIC	INJ VINCRISTINE (PHARMACRISTINE) 2 mg
20	PHARMEDIC	INJ METHOTREXATE (PHARMATREXATE) 50 mg

NOTE:

All firms whose products are selected as per above list are directed to submit their contract agreement (sample provided in Bid Solicitation Documents uploaded on HMC Website) within 10 (ten) days of this notice, with the rates offered mentioned in the contract agreement.